TAC 101

11/01/2001 - "Immunohistochemical analysis with antibody against the endothelial marker CD31 revealed a significant reduction in microvessel density in liver metastases from animals treated with TAC-101 (8 mg/kg p.o.), compared to liver metastases from the untreated control animals. "
09/01/2000 - "More pronounced life-prolonging effect was observed in the experimental liver metastasis model of A549, where T/C of 215% was observed following administration at 4 mg/kg/day of TAC-101. "
09/01/2000 - "TAC-101 showed the life prolonging effect in a model of experimental liver metastasis of TMK-1. "
05/01/1998 - "The growth inhibitory effect of TAC-101 on AZ-521 experimental liver metastasis was observed when treatment was started on day 7, 14, or 21 which may correspond to the progressive stage of liver metastasis in clinical settings. "
08/20/2003 - "These findings suggest that TAC-101 may improve therapeutic efficacy for liver cancer patients to prevent intrahepatic metastasis."

09/01/2004 - "Furthermore, TAC-101 (8 mg kg(-1) day(-1) orally for 30 days) was investigated in nude mice with subcutaneous RMG-II tumors. "
09/01/2000 - "However, TAC-101 did not show the direct anti-tumor effect against the established A549 tumor xenografts after subcutaneous implantation. "
09/01/1999 - "administration of TAC-101 inhibited tumor-induced angiogenesis in vivo and decreased the weights of L5 tumors in the mouse liver. "
10/01/1998 - "In summary, these results suggest that TAC-101 would be useful for a new class of therapeutic agents and that it may improve the prognosis of patients with liver-tumors including metastasizing tumor and HCC."
01/01/1998 - "Treatment with more than 10 microM TAC-101 for 24 h showed direct cytotoxicity against tumor cells in vitro. "

09/01/1999 - "We demonstrated in this study that inhibition of intra-hepatic growth of colon cancer by TAC-101 is mediated by inhibition of angiogenesis. "
03/01/2007 - "Using time-dependent FACScan analysis, it was observed that TAC-101 induced apoptosis in a DLD-1 human colon cancer cell line. "
01/01/2005 - "Moreover, evaluation of apoptosis by TAC-101 in vitro using FACScan analysis was performed in the DLD-1 human colon cancer cell line. "
01/01/2005 - "Apoptotic induction by TAC-101 was investigated using a rat hepatic metastatic model of rat RCN-9 colon cancer cells in vivo and FACScan analysis with the DLD-1 human colon cancer cell line in vitro. "
01/01/2004 - "We investigated the mechanism of the antiangiogenic effect of TAC-101 using a rat hepatic metastatic model in vivo and DLD-1 human colon cancer cells in vitro. "

09/01/2004 - "We examined the antitumor activity of TAC-101 against human ovarian carcinoma cell lines. "
09/01/2000 - "Mice implanted by intrasplenic injection of TMK-1, human gastric carcinoma cells, were used to examine the life-prolonging effect of TAC-101. "
03/01/2008 - "The antitumor effect of TAC-101 alone or combined with cisplatin was tested using human ovarian carcinoma. "
09/01/2004 - "Oral TAC-101 shows potential as a novel antitumor agent for ovarian carcinoma, especially ovarian clear cell adenocarcinoma."
01/01/1998 - "We found that oral administration of the benzoic acid derivative, TAC-101 ¿4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid¿ significantly inhibited experimental liver metastasis of murine colon 26-L5 carcinoma cells, whereas all-trans-retinoic acid (ATRA) did not show any inhibitory effect. "

05/01/1998 - "TAC-101, a benzoic acid derivative, inhibits liver metastasis of human gastrointestinal cancer and prolongs the life-span."
11/01/2001 - "TAC-101 (4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid) is a novel, synthetic retinoid that is effective against liver metastases of human gastrointestinal cancer cells such as the human stomach carcinoma line AZ-521 in animal models, and is currently in use in phase I cancer trials. "